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Abstract
For therapeutic purposes, non-small cell lung cancer (NSCLC) has traditionally been regarded as a single disease. However,
recent evidence suggest that the two major subtypes of NSCLC, adenocarcinoma (AC) and squamous cell carcinoma (SqCC)
respond differently to both molecular targeted and new generation chemotherapies. Therefore, identifying the molecular
differences between these tumor types may impact novel treatment strategy. We performed the first large-scale analysis of
261 primary NSCLC tumors (169 AC and 92 SqCC), integrating genome-wide DNA copy number, methylation and gene
expression profiles to identify subtype-specific molecular alterations relevant to new agent design and choice of therapy.
Comparison of AC and SqCC genomic and epigenomic landscapes revealed 778 altered genes with corresponding
expression changes that are selected during tumor development in a subtype-specific manner. Analysis of .200 additional
NSCLCs confirmed that these genes are responsible for driving the differential development and resulting phenotypes of AC
and SqCC. Importantly, we identified key oncogenic pathways disrupted in each subtype that likely serve as the basis for
their differential tumor biology and clinical outcomes. Downregulation of HNF4a target genes was the most common
pathway specific to AC, while SqCC demonstrated disruption of numerous histone modifying enzymes as well as the
transcription factor E2F1. In silico screening of candidate therapeutic compounds using subtype-specific pathway
components identified HDAC and PI3K inhibitors as potential treatments tailored to lung SqCC. Together, our findings
suggest that AC and SqCC develop through distinct pathogenetic pathways that have significant implication in our
approach to the clinical management of NSCLC.
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Introduction
Lung cancer is the leading cause of cancer-related deaths
worldwide and despite current treatments, prognosis remains
poor, with a five year survival of ,18% [1,2,3]. Non-small cell
lung cancer (NSCLC) and small cell lung cancer (SCLC) are the
two main histologic groups. SCLC arises mainly in the central
airways while NSCLC may occur centrally or peripherally. The
differing pathology of the two types is reflected in their clinical
management.
NSCLC is a heterogeneous disease with squamous cell
carcinoma (SqCC) and adenocarcinoma (AC) being the predom-
inant histological subtypes. Traditionally, these subtypes have
been treated as a single disease entity with treatment strategies
determined solely by disease stage. However, recent evidence from
clinical trials has demonstrated that histological subtypes of
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37775NSCLC respond differently to both targeted drugs and newly
developed chemotherapies, possibly related to differences in cell
derivation and pathogenetic origins [3,4,5,6,7,8,9]. One of the
most striking examples is the folate antimetabolite Pemetrexed,
which exhibits superior efficacy and is restricted for use in patients
with non-SqCC, presumably due to the higher expression of
thymidylate synthase in SqCC tumors [9]. Likewise, numerous
studies have associated a higher response rate upon treatment of
AC with the EGFR tyrosine kinase inhibitors Gefitinib and
Erlotinib, reflecting the higher prevalence of EGFR mutations in
this subtype [6,10]. These discrepancies in tumor biology and
clinical response highlight the need to determine the underlying
genetic, epigenetic and metabolic similarities as well as differences
between the NSCLC subtypes in order to define more appropriate
avenues for therapeutic intervention.
Initial gene expression profiling studies were able to segregate
AC and SqCC tumors into their respective histologic groupings
based on multi-gene models; however, critical events in tumorgen-
esis may be masked by reactive changes when examining
expression profiles alone [11,12,13]. Conversely, DNA copy
number or DNA methylation changes corresponding with gene
expression changes are often regarded as evidence of causality.
Such DNA level changes are critical deregulation events driving
progression and other cancer phenotypes [14,15,16]. Since SqCC
and AC are thought to develop from distinct cell lineages in
different regions of the lung, the range of genetic alterations
required for tumor initiation may occur in a lineage-restricted
manner. For example, the amplification of the lineage survival
oncogenes SOX2 and TITF1/NKX2-1 have recently been identi-
fied as key events specific to the development of lung SqCC and
AC, respectively [17,18]. However, these genes alone are
insufficient to explain the phenotypic diversity of the subtypes,
suggesting that the vast majority of genes responsible for their
differential development remain unknown. Although genetic and
epigenetic differences between SqCC and AC have been
described, low genome coverage and/or small sample sizes have
been limiting [19,20,21,22,23,24].
Inthisstudy,weperformedthefirstlarge-scaleanalysisofprimary
NSCLCtumors(261total–169ACand92SqCC), integratinghigh
resolution DNA copy number, methylation and gene expression
profiles to identify critical subtype-specific molecular features. The
characterization of the genomic and epigenomic landscapes of AC
and SqCC revealed an astounding number of differences at the
DNA level with subsequent gene expression changes that are
selected for during subtype-specific lung tumor development.
Importantly, we identified key oncogenic pathways disrupted by
these alterations that likely serve as the basis for differential
behaviors in tumor biology and clinical outcomes. Lastly, through
prognostic analysis and in silico screening of candidate therapeutic
compounds using subtype-specific pathway components, we show
how these new findings may influence our approach to the clinical
management of NSCLC.
Results
Assessment of global genomic instability in AC and SqCC
Carcinomas of all types are known to harbor many DNA-level
alterations linked, in part, to carcinogen exposure [25]. Indeed,
tobacco smoke has been linked to the induction of not only DNA
mutations, but also broad chromosomal instability [26]. Based on
the differing exposure to tobacco carcinogens of cells in the central
(SqCC) and peripheral (AC) airways, we sought first to determine
whether global genomic instability was more prevalent in either of
the two subtypes. We generated and compared whole genome
copy number profiles for 261 NSCLC tumors 169 AC and 92
SqCC – by tiling-resolution array comparative genomic hybrid-
ization (CGH) (Sample Set #1, Table S1) [27,28,29,30]. After
hybridization, standard removal of systematic biases, and compu-
tational segmentation to identify regions of gain and loss, the
number of gained, lost, and neutral probes was assessed for each
tumor. The relative genomic instability observed in AC and SqCC
groups was then compared (Figure 1a). The average number of
altered probes (per sample) was compared between groups using
the Mann-Whitney U-test. No significant differences between the
two subtypes were found, consistent with previous work that
showed similar DNA content across subtypes [31]. This analysis
demonstrates that neither subtype has a proclivity for gain or loss
of DNA. Therefore, observed differences in alteration frequency at
a given locus can be attributed to sub-type specific selection of
genes included within altered regions and not to different degrees
of random genomic instability associated with tumor development.
Disparate genomic landscapes characterize lung SqCC
and AC
Although the NSCLC subtypes exhibit similar levels of genomic
instability, if specific genetic pathways are involved in their
differential development, differences in the genomic alterations
selected during tumorigenesis should be present. To determine if
genetic alterations unique to each NSCLC subtype exist, we
looked for recurrent non-random regions of aberration in each
group. Samples were grouped by subtype and probes were
aggregated into regions based on similar copy number status. The
frequency of alteration across autosomes was determined and
compared between subtypes using the Fisher’s exact test and the
resulting p-values were corrected for multiple comparisons with a
cut-off of #0.01 considered significant. In addition, we required
regions to be altered in .20% of samples from a subtype group
and a difference between groups of .10% to be considered ‘‘of
interest’’. Figure 1b displays the resulting genomic landscapes of
AC and SqCC based on the frequency of gain and loss across the
genome, and highlights the corresponding regions of difference
between the subtypes that were identified.
This analysis revealed 294 regions of copy number disparity
between SqCC and AC, 205 of which were SqCC-specific,
whereas 89 were AC specific (Table S2). Although some regions
overlapped, the character of the alteration (i.e. gain versus loss)
was specific to an individual group. Since the alteration status
between the subtypes differed strongly, we classed these as
subtype-specific copy number alterations. In total, these alterations
covered approximately 550 Mbp of the genome, ranging in size
from large segments on chromosome arms (64.8 Mbp on 4q) to
discrete peaks only kilobases in size (0.05 Mbp in multiple places).
Interestingly, copy number profiling of 20 preinvasive lung
carcinoma in situ lesions, the assumed precursors to lung SqCC
tumors, revealed that the vast majority (186/204, ,92%) of SqCC-
specific alterations are present at this stage of tumor development,
suggesting that these events may commence early in SqCC
tumorigenesis(Table S3).Theremainingalterationsthatarepresent
intheSqCCtumorsandnotfoundinthecarcinomainsitulesionsmay
represent potential drivers of SqCC progression (Table S3, with
potential target genes of these regions identified in Table S4,
discussed below). Together, these findings support our hypothesis
that the subtypes develop through different genetic pathways.
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manner during NSCLC development
The discovery of DNA copy number disparities between
NSCLC subtypes suggests that genes within these areas might be
preferentially selected during tumorigenesis and thus, responsible
for the differential development and pathological characteristics of
the subtypes. To identify the potential target genes of these
alterations, we integrated DNA copy number and gene expression
levels [32]. Gene expression profiles were generated for a subset of
tumors that were analyzed by array CGH (20 SqCC and 29 AC
Figure 1. Genomic landscapes of lung AC and SqCC. (a) Percentage of clones of each state in both subtypes. Box plots illustrate the
percentage of clones with status 21 (loss/deletion), 0 (neutral), and +1 (gain/amplification) in each of the subtypes. Percentages were calculated for
each sample and for each status. These plots demonstrate the similarity in total genome alteration percentages between AC and SqCC tumors and
suggest that recurrently altered regions of genome are the result of selection rather than a higher frequency of gain or loss of DNA in either subtype.
(b) Alteration frequencies for 169 AC (red) and 92 SqCC (blue) tumors are displayed across the entire human genome. Solid vertical black lines
represent chromosome boundaries whereas the dotted black lines represent chromosome arm boundaries. The frequency of copy number gain is
denoted in the top panel. Note the high frequency of 3q gain in the SqCC subtype, consistent with previous reports. Additional regions of copy-
number difference are also clear, such as the more common gain of chromosome 2p in AC. The second panel (middle) shows the frequency of copy
number loss. Common tumor suppressor gene loci such as chromosome 3p are common between AC and SqCC, but large differences exist in regions
such as chromosome 4q. The significance of copy number disparity (inverse p-value corrected for multiple comparisons) between AC and SqCC
subtypes is depicted in the third (bottom) panel. Solid black lines represent regions considered statistically different (p#0.01) whereas grey lines are
not.
doi:10.1371/journal.pone.0037775.g001
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targeted by subtype-specific alterations would be different at the
DNA level with matching differences at the gene expression level.
Further, we also analyzed normal lung tissue to ensure that only
genes differentially expressed in tumor tissues (relative to normal)
remained as candidates, a characteristic consistent with a role in
tumor development.
Genes located within each subtype-specific copy number
alteration were identified and the expression levels compared
between the SqCC and AC samples to determine those that were
differentially expressed (p,0.001, after multiple testing correc-
tion). For SqCC, 4669 unique genes mapped to the subtype-
specific copy number alterations (,23 genes per region), and 797
(17%) of these were differentially expressed between subtypes in
the anticipated direction. In AC, 2050 unique genes were located
in subtype-specific copy number alterations (,23 per region) and
171 (8%) were differentially expressed between subtypes in the
anticipated direction.
Although some genes overlapped, their disruption patterns were
specific to the individual cancer type, suggestive of opposing roles
(oncogenic vs tumor suppressive) depending on cellular context.
Thus,thesegeneswerealsoconsideredtobesubtype-specifictargets.
When combined, the SqCC and AC subtype-specific copy number
regulated candidates represented 968 unique genes and showed a
clear distinction in expressionlevels between the two subtypes.
In addition to demonstrating a relationship between expression
and copy number alteration, a candidate subtype-specific gene was
also required to be deregulated in cancer tissues relative to normal
tissue [33]. We analyzed the expression levels of candidates in an
independent panel of 53 SqCC and 58 AC lung tumors and 67
samples of exfoliated bronchial cells from cancer-free individuals
(Sample Sets #3 and #4, Table S1). In total, 655 of the 797
SqCC-specific and 143 of the 171 AC-specific genes had
corresponding probes on this array platform. These genes were
compared between the respective cancer subtype and the normal
bronchial cells in order to determine those that were significantly
differentially expressed (p,0.001) in the direction predicted by the
corresponding copy number alteration in which they were located.
This analysis revealed that 447 (68%) of the SqCC-specific and 71
(49%) of the AC-specific genes were deregulated in cancerous
tissues (492 unique gene alterations, Table S4). Since these genes
met all three criteria for defining candidate subtype-specific, copy
number alteration regulated targets as described above, we
concluded they might represent the critical gene alterations
driving the development of each subtype (Figure 2).
Different oncogenic pathways are associated with the
development of AC and SqCC
Cellular pathways and processes specifically disrupted in
individual subtypes may reveal key oncogenic mechanisms driving
the differential development of AC and SqCC. Thus, after
identifying the genes responsible for the differences between the
subtypes, we next wanted to investigate their biological functions.
To discover subtype-related networks of biologically related genes
we performed Ingenuity Pathway Analysis (IPA) of the 71 AC and
447 SqCC specific target genes (Figure 3, Table S5). SqCCs
exhibited disruptions in gene networks that function in regulating
DNA replication, recombination and repair, with additional roles
in lymphoid tissue structure and development (Table S4). Genes
involved in the top SqCC network were associated with the
binding and modification of histone protein H4, as well as the
regulation of the NFKB complex (Figure 3b). In contrast, the
primary networks in AC displayed functions associated with cell-
to-cell signaling, development, and drug metabolism (Table S5).
The main AC-specific gene network was composed primarily of
genes regulated by the transcription factor HNF4a (Figure 3a),
whereas AC network 2 contained numerous genes controlled by
TGFb and TP53. The differential disruption of gene networks in
AC and SqCC was further suggestive of distinct mechanisms of
tumorigenesis for the subtypes.
Global subtype variations in DNA methylation levels
reflect differences in cells of origin
Unlike the genome, which is identical for most normal cells in
the body, the epigenome differs between tissue types [34,35].
Similarly, cancer genomes exhibit global hypomethylation to
varying degrees depending on the tissue of origin [36]. DNA
methylation profiles are also influenced by mutational profiles
within different cancer types, as DNA hyper- and hypomethylation
alterations are also known to be related to tissue and genetic
background [37] as well as smoking behavior [38]. Given the
differing mutational spectra of the two NSCLC subtypes and their
likely differing cells of origin, we investigated the overall DNA
methylation level of 30 AC and 13 SqCC samples (Sample Set #4,
Table S1). To enable comparisons of SqCC and AC tumors to
appropriate matched normal cells, DNA methylation profiles were
also generated for 30 non-malignant lung parenchyma samples
(AC reference) and 18 histologically normal exfoliated bronchial
epithelial cell samples (SqCC reference) from patients with
NSCLC (Sample Set #1, Table S1). Analysis of 27,578 CpG
dinucleotides probes within .13000 CpG islands shows that DNA
methylation in the bronchial epithelia and the SqCC tumors was
slightly lower than in the normal lung or AC tumors (Figure 4a).
Figure 2. Differential expression as a result of subtype specific
copy number alterations. Transformed absolute expression data for
the 492 unique genes exhibiting disruption in expression levels as a
result of copy number differences are displayed. In addition, these
genes are up or down-regulated in the subtype which they are
disrupted compared to normal lung tissue (see results). High-level
expression is indicated by red while black indicates progressively lower
levels of expression. The AC samples are indicated by red highlighting
on the top of each column, while SqCC samples are indicated by blue
highlighting. Each gene is sorted according to its chromosomal
position. There is a clear distinction in the expression of these genes
indicating their specific involvement in the subtypes.
doi:10.1371/journal.pone.0037775.g002
The Molecular Basis of Lung Cancer Subtypes
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of CpG islands, suggesting that the cells of the central airway are
globally hypomethylated relative to the cells of the peripheral
airways, whether cancerous or not (Figure 4b). In this case the two
groups are significantly different when compared using a Mann-
Whitney U test (p,0.0001).
To determine whether these trends were evident in tumor-
specific epigenetic alterations, (i.e. those that exist within the tumor
subtype when compared to an appropriate normal cell), we
compared the differential methylation profiles of AC and SqCC
tumors. These profiles were generated by subtracting the average
normal DNA methylation profile for the references from each of
Figure 3. Gene networks involved in the development of SqCC and AC. Ingenuity Pathway Analysis was used to identify biologically related
networks from the subtype specific genes deregulated by subtype-specific copy number alterations (see Methods). The top resultant gene networks
for each subtype are displayed. a) AC network #1 of genes related to HNF4 signaling. b) SqCC network #1 displaying potential interactions between
multiple histone regulating genes for both a) and b), solid lines denote direct interactions while dotted lines represent indirect interactions between
the genes. Network components highlighted in red are upregulated in the corresponding subtype whereas those highlighted green are
downregulated. Those not highlighted are used by the software to display relationships. Additional information about the genes and their
interactions can be found at www.ingenuity.com. or within the discussion. In this diagram molecules are represented as such; corkscrews represent
enzymes, y-shaped molecules are transmembrane receptors, thimble-shaped molecules are transporters, kinases are triangular, and circular
molecules encompass all other gene products.
doi:10.1371/journal.pone.0037775.g003
Figure 4. Global DNA methylation patterns of NSCLC tumors and associated normal tissues. Comparison of average DNA methylation
levels between AC tumor, AC normal (histologically normal lung parenchyma), SqCC tumor, and bronchial epithelia. a) CpG island probe averages.
The average of each of the profiles at probes located within CpG islands is plotted as a component within the box plot. In this panel, SqCC and
bronchial epithelia samples appear to have slightly lower DNA methylation levels than the AC tumor and AC normal groups. b) Non-CpG island probe
averages. The average of each of the profiles at probes not located within CpG islands is plotted as a component within the box plot. In this figure b-
value is the level of methylation as defined by the methylated signal/total signal for each probe. In this panel, SqCC and bronchial epithelia are
significantly lower in methylation level compared to the AC tumor or AC normal groups, indicating that outside of CpG islands, where the bulk of
genomic methylation occurs, the central airway samples are more hypomethylated. c) Average differential methylation levels at CpG islands. The
average differential is plotted for the 30 AC samples and the 13 SqCC samples. The two groups are very similar in their differential profile within CpG
island probes. d) Average differential methylation levels at CpG sites not located within CpG islands. In this plot the average differential methylation
level is plotted for probes that are not located within CpG islands. Again, the two groups are not significantly different by a Mann-Whitney U test.
doi:10.1371/journal.pone.0037775.g004
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assessment of copy number alterations (gain and loss), there were
no significant differences between the AC differential profiles and
the SqCC differential profiles (Figure 4c) in CpG island probes or
non-CpG island probes (Figure 4d). Based on this, we again
reasoned that any observed differences in hypermethylation or
hypomethylation frequencies between the subtypes are likely to be
due to subtype-specific selection of these alterations.
Different epigenetic alterations are involved in the
development of AC and SqCC subtypes
Although no differences in global methylation changes were
observed between subtypes, the two subtypes may possess
differential alteration frequencies at individual loci. To determine
whether AC and SqCC tumors possess locus-specific differences in
DNA methylation, we examined the frequencies of methylation
alteration at gene-associated loci in both subtypes. Tumor DNA
methylation levels were compared to the average of available
normal reference tissue profiles. The frequency of probe
hypermethylation and hypomethylation (tumor–normal |$0.15)
in AC and SqCC samples was compared using the Fisher’s exact
test. Following correction for multiple comparisons, 2708 probes
corresponding to 2384 genes were found to be differentially
methylated (p#0.05). The SqCC group contained markedly more
recurrently hyper- and hypomethylated loci than the AC group,
similar to the disparity in the numbers of subtype-specific copy
number-regulated genes observed in the analysis of genomic
alterations. In fact, only 8% of the 2708 significant probes were
more frequently altered in AC, the rest being more commonly
hyper- or hypomethylated in SqCC.
Tofurtherrefinethelistofdifferentiallymethylatedgenestothose
whose gene expression reflects levels expected based on their
epigenetic alteration, we assessed the 2384 genes with differential
methylationfor differential expressionbetweenthesubtypes,aswell
as differential expression from normal tissues, using a corrected p-
value threshold of p,0.05. 32 AC candidate genes and 297 SqCC
genes met these stringent criteria and were further analyzed as
subtype-specific epigenetically regulated genes (Table S6).
Epigenetically regulated genes complement genetically
regulated genes
To determine whether the 32 AC-specific and 297 SqCC-
specific epigenetically-regulated genes carried out functions similar
to those subtype-specific genes discovered by the DNA copy
number analysis described above, pathway disruption analysis was
performed. This revealed that the most significant epigenetically-
regulated gene network in AC is involved in cell cycle, cell death,
and cellular development (Table S7). This is partly in contrast to
the top AC network of copy number regulated genes, which
similarly have functions associated with tissue development, but
also possess cell signaling and hematological system function in
common (Table S4). The overall degree of similarity between AC-
specific genes that are genetically or epigenetically regulated is
quite small, likely due to the low number of AC-specific genes
identified (potential reasons for this are discussed below). In
contrast, the SqCC gene networks in both analyses are very
similar. For example, DNA replication, recombination and repair
are highly featured functions of genes identified by both DNA
copy number and DNA methylation analyses of SqCC (Tables S5
and S7, respectively). Additionally, genes involved in immunolog-
ical disease and lymphoid tissue structure and development were
prominent. Of particular interest was the enrichment of aberrantly
methylated genes in the small cell lung cancer signaling pathway
(comprised of genes known to deregulated in small cell lung cancer
as annotated by Ingenuity) (Figure 5a). This was the most
significantly enriched canonical pathway in either subtype that was
affected by DNA methylation alterations and it is of interest
because both of these lung cancers (SCLC and SqCC) arise in the
central airways with similar exposure to cigarette smoke carcin-
ogens. E2F1 is among the hypomethylated and overexpressed
genes represented in this pathway, and is known to be
overexpressed in SCLC and to drive expression of EZH2, which
is also overexpressed in SCLC [39,40]. To explore this pathway
further, we investigated whether EZH2 was more highly expressed
in SqCC than AC tumors (as a consequence of differential E2F1
expression). As expected, we found that EZH2 was expressed at a
significantly higher level in SqCC tumors than AC tumors,
demonstrating the biological consequence of E2F1 disruption
(Figure 5b). The differential expression of EZH2 in the two
subtypes is significant, given the numerous differences in aberrant
DNA methylation observed between subtypes; this could reflect
the key role of EZH2 in the polycomb group, a protein complex
involved in DNA methylation [41].
DNA copy number and DNA methylation data are comple-
mentary from a gene-specific perspective as well. This is
highlighted by seven genes (ATP2C1, PCYT1A, ZWILCH,
CENTB2, BAG4, PARP11 and CSDA, Table S8) that are disrupted
by gene-dosage in one subtype and DNA methylation in the other.
PARP11 is one such example of differential activation/inactivation
by DNA copy number and DNA methylation, which is discussed
further below.
Concerted genetic and epigenetic disruption of subtype-
specific genes
In order to determine if both DNA copy number and DNA
methylation aberrations simultaneously disrupted any genes, we
combined the subtype-specific gene lists derived using the two
analytical approaches described above (Table S9). Combining the
71 AC genes identified through their association with DNA copy
number alteration and the 32 genes associated with DNA
methylation aberrations did not yield any overlapping genes. This
result was not surprising given the observed lack of similarity at the
level of function/network analysis. In SqCC however, combining
the 447 copy-number associated genes with the 297 DNA
methylation genes yielded overlap of 38 genes (Table S9). These
genes exhibit frequent concurrent genetic, epigenetic, and
subsequent gene-expression alterations that discriminate them
from AC tumors. Notably, the well-known 3p tumor suppressor
gene (TSG) FHIT was among these genes. The differential
methylation levels of FHIT are shown in Figure 5c. Loss of FHIT
expression is associated with smoking and is more frequent in
SqCC tumors than AC tumors, consistent with our data
[42,43,44]. Hypermethylation of this gene has also been investi-
gated as a potential biomarker for centrally-occurring lung cancers
[45,46]. Concerted genetic and epigenetic disruption was not
limited to hypermethylation/loss however, as numerous genes
displayed hypomethylation coupled with increased copy number
and gene expression in SqCC. For example, BRF2, which we
recently identified as a lineage specific oncogene in lung SqCC,
was deregulated in this manner, highlighting its importance to the
development of this lung cancer subtype [47]. Furthermore, in
addition to those genes previously associated with lung cancer,
TSGs and oncogenes known to be deregulated in other cancer
types–such as PRDM2 and SIAH2, respectively – were also altered
at the genetic, epigenetic and gene expression levels. Such
multidimensional disruption is indicative of strong selective
The Molecular Basis of Lung Cancer Subtypes
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suggesting that these genes may play a pivotal role in SqCC.
Subtype specific genes are responsible for AC and SqCC
phenotypes
Next, we aimed to confirm that the genes differentially disrupted
atthegenomicandepigenomiclevelareresponsibleforthedifferent
biological characteristics ofACand SqCC.Sincetheyareregulated
by subtype specific alterations, we hypothesized that the expression
levels of these genes should be able to accurately segregate NSCLC
tumorsintodistinctACandSqCCgroups.Aspredicted,whenusing
the expression values for the 49 NSCLC tumors from our data set,
principle component analysis with the 778 unique genetically and/
or epigenetically deregulated genes clearly delineated distinct
subtype specific clusters (Figure 6a). A receiver operating charac-
teristic (ROC) area under the curve (AUC) value of 0.9690
(P,0.0001) confirmed that principle component 1 was a strong
discriminator of the subtypes (Figure 6a). This was not surprising as
thegeneswereuncoveredbasedondifferencesbetweenthesubtypes
usingthissamesetofsamples.Therefore,tofurtherconfirmtherole
ofthegenesinsubtypedevelopment,weappliedthesameanalysisto
twoindependentsamplesetsgeneratedbydifferentinstitutions.The
first consisted of 111 (58 AC and 53 SqCC, Sample Set #3,
Table S1) and the second of 138 (62 AC and 76 SqCC, Sample Set
#6,Table S1)clinicallungtumors[48].Strikingly,thisanalysiswas
also able to separate the AC and SqCC samples with a great deal of
accuracy (ROC AUC values of 0.9076 and 0.9442, P,0.0001,
respectively) (Figure 6b and c). Validation in these large, indepen-
dent panels of NSCLC tumors from separate institutions provides
further evidence that the genes regulated by subtype specific
genomic and epigenomic disruptions are responsible for driving the
differentialdevelopmentofACandSqCC.Furthermore,ourresults
highlight the impact of this novel integrative genome, epigenome
andtranscriptomeanalysisinidentifyingrobusttargetgenesthatcan
be used as biomarkers of disease.
Subtype-specific genetic differences are translated to the
protein level
In order to confirm that the genome and transcriptome
differences between the subtypes affect the relative protein levels
of the identified genes, we performed immunohistochemical (IHC)
analysis on a large, independent panel of .200 lung tumors.
Protein levels for three subtype specific genes with available
antibodies validated for IHC were analyzed: ERCC1 (inactivated
in AC), KEAP1 (inactivated in AC) and SOX2 (activated in
SqCC) (Figure 7). Average protein levels for all three genes were
significantly different between the subtypes in the direction
predicted by the integrative genetic and epigenetic analysis
(Figure 7a, d, and g). The average immunohistochemical nuclear
ERCC1 expression was much lower in AC tumors (43.4565.389,
N=175) compared to SqCC tumors (79.9969.095, N=106, two-
tailed p,0.001, unpaired t test with Welch’s correction) consistent
with this gene being inactivated specifically in AC. Similar results
were seen for cytoplasmic levels of KEAP1, which is also
inactivated specifically in AC (AC: 126.564.179, N=184; SqCC:
160.965.401, N=110, two-tailed p,0.0001, unpaired t test with
Welch’s correction). Conversely, nuclear levels of SOX2, which is
activated specifically in SqCC, were significantly higher in this
subtype (206.568.839, N=106) than in AC (70.3966.342,
N=170, two-tailed p,0.0001, unpaired t test with Welch’s
correction). Together, these data demonstrate that the genomic,
epigenomic and gene transcription differences between the
subtypes are translated to the protein level, providing more
credence to the hypothesis that these changes have a functional
consequence on the phenotypes of AC and SqCC.
Subtype-specific genes are associated with distinct
clinical characteristics in AC and SqCC
We next aimed to determine the influence of the subtype
specific genes on the clinical characteristics of AC and SqCC.
Since these genes are responsible for defining the distinct biology
of these diseases, we reasoned that their expression should only
correlate with specific clinical features in one subtype and not the
other subtype or NSCLC (AC + SqCC) in general. To test this, we
determined the survival associations using a Mantel-Cox log rank
test for each of the 778 subtype specific genes in AC, SqCC and
NSCLC in the dataset with overall survival information available
(Sample Set #3, Table S1). Collectively, this analysis revealed 131
AC and 46 SqCC specific genes that had significant (P,0.05)
associations with overall survival (Table S10). Remarkably, the
associations were completely specific to an individual subtype as
no genes were correlated with survival in the same manner across
both subtypes. Six genes (DSG2, PLAC2, ATP9A, TPM4, CD9 and
PSMD11) were significantly associated with survival in both
subtypes; however, they displayed a completely opposite pattern
in terms of survival with low expression associated with poor
survival in one subtype and high expression with poor survival in
the other (Figure 8). Thus, although associated with survival in
both subtypes, the genes exhibit distinct subtype-specific associa-
tions. Interestingly, low levels of CD9 expression have been
previously implicated in the poor prognosis of lung cancer patients
[49]. However, we now show that this association is subtype
specific with low levels of CD9 correlated with poor prognosis in
SqCC and high levels with poor prognosis in AC (Figure 8).
Importantly, only eight genes that were associated with survival in
one of the subtypes were also significant when analyzing NSCLC
as a whole, providing further evidence to the importance of
treating the subtypes as separate disease entities. Together, these
findings underscore the potential clinical relevance of subtype
specific alterations.
Defining putative treatment strategies tailored to lung
cancer subtypes using in silico screening of candidate
therapeutic compounds
Lastly, after defining and validating our AC and SqCC specific
cancergenes,weappliedthesefindingstodefinepotentialtreatment
strategies tailored to each lung cancer subtype. To do this, we
queried the Connectivity Map (CMAP) database using our subtype
Figure 5. Epigenetically altered SqCC genes are significantly enriched for SCLC signaling. a) SCLC signaling components altered by DNA
methylation in SqCC. In this schematic of the SCLC signaling pathway, genes that are hypomethylated and overexpressed are shown in red, and those
that are hypermethylated and underexpressed are shown in green. Components at all levels of the pathway are affected, including the transcription
factor E2F1, which drives the expression of the oncogenic polycomb group member EZH2.b )EZH2 expression in 58 AC tumors and 53 SqCC tumors.
EZH2 expression was assessed in an external dataset, and it was found to be higher, as predicted, in SqCC tumors compared to AC tumors using a
Mann-Whitney U test (p,0.0001). c) FHIT differential methylation levels in SqCC and AC tumors. FHIT was shown to be deregulated by both deletion
and hypermethylation in a manner that was specific to SqCC tumors. Show here are the differential DNA methylation levels for 30 AC tumors and 13
SqCC tumors. The SqCC tumors are hypermethylated to a much higher degree than the AC tumors, consistent with previous published findings.
doi:10.1371/journal.pone.0037775.g005
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37775Figure 6. Subtype specific genes explain AC and SqCC phenotypes. Principal components analysis was performed utilizing all genes
demonstrating expression differences between the subtypes as a result of genetic and/or epigenetic alterations using: A) Data generated for 49
NSCLC tumors (29 AC, 20 SqCC) as part of this study which was used in gene discovery; B) Publically available data from 111 NSCLC tumors (58 AC
and 53 SqCC, Dataset #3-Duke, Table S1) used as test set #1; C) Publically available data from 138 NSCLC tumors (62 AC and 76 SqCC, Dataset #6-
Samsung, Table S1) used as test set #2. Red circles indicate AC samples, while the blue circles indicate SqCC samples. Strong separation of the AC
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expression direction of each signature. The CMAP consists of
thousands ofgene expression profilesfrom different cancer cell lines
treated with a vast collection of small molecules [50]. By comparing
the subtype specific signatures of up and down regulated genes with
preexisting small molecule response signatures in the database, the
program can identify small molecules whose effects on gene
expression changes are positively or negatively correlated. Negative
correlation scoresimply thatthe matchedmolecules haveamode of
action that can reverse the expression direction of query genes, and
therefore serve as potential therapeutic compounds. Using this in
silico screening approach, we identified numerous instances (cell
line/treatment combination) that were significantly correlated with
both the AC and SqCC specific gene signatures identified in our
study (Table S11). Remarkably, SqCC had an expression signature
that was negatively correlated with multiple HDAC and PI3K/
mTORinstancesincludingtrichostatinA,vorinostat(alsoknownas
SAHA) and MS-275 (all HDAC inhibitors) and LY-294002,
quinostatin, sirolimus (also known as Rapamycin) and wortmannin
(all PI3K/mTOR inhibitors). These findings were interesting for
two reasons, firstly as the alteration of histone modifying enzymes
wasthemajornetworkdisruptedinSqCC(seeabove).Secondly,the
relevance of these epigenetically-targeted drugs is pertinent as we
identifiedconcerteddisruptionofPRC2componentsresponsiblefor
denovomethylationaswell.Inaddition,PIK3CAactivation(mutation
and/or amplification) is known to occur more frequently in SqCC
than AC [51] and many downstream components of this pathway
were also altered specifically in SqCC (Table S4). The CMAP
analysisforAC,ontheotherhand,wasnotveryinformative,asnone
of the negatively correlated molecules shared the same functions
(Table S10). Thismay be a byproduct of the heterogeneity between
AC tumors (discussed below).
To confirm the results from the CMAP analysis, we treated a
panel of six NSCLC cell lines (three AC and three SqCC) with the
HDAC inhibitor Trichostatin A, which was the most significantly
negative correlated HDAC inhibitor from the SqCC analysis.
and SqCC tumors along principal component 1 in all sets demonstrates the contribution of these genes to the differential phenotypes. On the right
are the respective ROC curves for each dataset using the respective principle component 1 values for each sample. AUC values of 0.9690, 0.9076 and
0.9442 for A), B) and C), respectively, suggest that the gene expression signature is an extremely good discriminator of the subtypes.
doi:10.1371/journal.pone.0037775.g006
Figure 7. Subtype-specific genomic differences are reflected at the protein level. Immunohistochemical analysis of protein levels for
ERCC1 (A–C), KEAP1 (D–F) and SOX2 (G–I) in squamous and adenocarcinoma lung tumors. Average immunohistochemical protein expression levels
for each subtype are plotted 6 SEM of each group. Representative microphotograps showing tumoral cells (arrows) with higher levels of
immunohistochemistry expression of nuclear ERCC1 (B and C), cytoplasmic KEAP1 (E and F) and nuclear SOX2 (H and I) in squamous cell carcinomas
(B, E and H) compared to lung adenocarcinomas (C, F, and I). Images are of samples reflecting the average protein expression for each group (ERCC1:
SqCC = ,80, AC = ,43; KEAP1: SqCC = ,161, AC = ,126; SOX2: SqCC = ,207, AC = ,70). Magnification 200x. * and ** = p,0.001 and
p,0.0001, two-tailed unpaired t test with Welch’s correction, respectively.
doi:10.1371/journal.pone.0037775.g007
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represented their respective clinical tumor subtypes by performing
principle component analysis with the subtype-specific genes using
publically available gene expression profiles for a large panel of
NSCLC cell lines (Figure S1). As predicted by the in silico analysis,
SqCC cell lines (average IC50=69 nM) were, on average, five
times more sensitive to Trichostatin A than AC cell lines (average
IC50=346 nM), a statistically significant difference (P=0.05,
Mann-Whitney U Test) (Figure 9).
Discussion
The emergence of tumor cells from normal precursors is
thought to involve a complex interplay between genetics and cell
lineage [8]. Due to the different cell types involved as well as the
attributes of an individual cell’s local environment or niche, it is
logical to assume different mechanisms are required in tumori-
genesis for each lung cancer subtype. Cell lineage may also have a
dramatic effect on the manifestation of genetic/epigenetic
alterations during the development of each lung cancer subtype
as only those promoting a malignant phenotype in the specific
cellular context will be selected and maintained [8]. Previous
studies suggest that distinct patterns of DNA alteration exist for
AC and SqCC; however, the specific genes responsible for the
different tumor phenotypes are largely unknown [20,21,22,52].
In this study, we provide the first comprehensive investigation of
the key genetic and epigenetic alterations distinguishing AC and
SqCC lung tumors. We achieved this by integrating whole-
genome DNA copy number, DNA methylation, and gene
expression data to identify genes altered in a subtype-specific
manner. These genes are associated with distinct gene networks in
each lung cancer subtype, flagging distinct signaling pathways as
contributing to tumorigenesis. We also found subtype-type specific
changes to be correlated with clinical outcomes and highlight
putative treatment strategies based on the subtype specific
molecular signatures.
The 294 subtype-specific copy number alterations detected in
this study demonstrate that different genetic pathways are involved
in the pathogenesis of AC and SqCC. Importantly, previously
identified lineage specific oncogenes including SOX2 and BRF2
were identified, validating our approach [17,47]. Although some
of the regions and genes have previously been shown to be
Figure 8. CD9 alteration and survival is different in AC and SqCC tumors. a) Low CD9 levels are associated with poor prognosis in SqCC. The
prognostic value of CD9 expression levels was evaluated in 53 SqCC tumors. Survival of the 1/3 lowest CD9 expressers is shown in red, and the top 1/3
is shown in blue. In this case, low expression of CD9 is significantly associated with poor prognosis when using a Mantel-Cox log test (p=0.035). b)
High CD9 levels are associated with poor prognosis in AC. The prognostic value of CD9 expression levels was evaluated in 58 AC tumors. Survival of
the 1/3 lowest CD9 expressers is shown in red, and the top 1/3 is shown in blue. In this case, low expression of CD9 is significantly associated with
poor prognosis when using a Mantel-Cox log test (p=0.029).
doi:10.1371/journal.pone.0037775.g008
Figure 9. SqCC cell lines are more sensitive to the HDAC
inhibitor Trichostatin A than AC cell lines. a) Dose-response
analysis of Trichostatin A on the relative viability of three AC (A549,
H3255 and H1395) and three SqCC (H520, HCC15 and HCC15) cell lines.
Each curve was generated from the average data points from four
separate experiments. b) Table with the average IC50 and SEM for each
cell line tested derived from four separate experiments.
doi:10.1371/journal.pone.0037775.g009
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newfound importance to a specific lung cancer subtype. For
example, previously identified oncogenes such as NOTCH3 and
FOXM1 were overexpressed through increased gene dosage
specifically in SqCC while the tumor suppressor KEAP1 was
deleted and underexpressed specifically in AC [53,54,55]. This is
the first report suggesting that these previously established lung
cancer-associated genes are actually involved in subtype-specific
tumorigenesis.
A broader gene network-based analysis of the copy number-
regulated genes revealed additional insights into the differential
oncogenic mechanisms driving the pathogenesis of AC and SqCC.
The top SqCC gene network was mainly associated with DNA
replication, recombination and repair. In addition to these
functions, histone modification genes were represented as well.
Histones are fundamental building blocks of eukaryotic chromatin
and are involved in myriad cellular processes, including replication,
repair, recombination and chromosome segregation [56,57,58].
Recently, global alterations of histone modification patterns have
been reported in human cancers [59]. Our data suggest that direct
deregulation of histone modification enzymes including ASF1B,
PRMT1, SAE1, SET8, CHAF1A and UHRF1 may drive this
phenomenon and play a key role during the development of lung
SqCC. As histone modifications also play an essential role in DNA
replication, there may be a synergistic effect between the histone
modifying genes and replication/recombination associated genes
that contribute to tumor development. Interestingly, histone
modification alterations occur more frequently in lung SqCC than
AC, consistent with our findings [60].
The gene network detected as perturbed in AC subtype tumors
contained genes mainly involved in regulating tissue development
and cell-to-cell signaling and known to be targeted by the
transcription factor HNF4a. HNF4a regulates a large set of genes
in a cell-specific manner and is necessary for cell differentiation
and maintenance of a differentiated epithelial phenotype [61]. In
other carcinomas, deregulation of HNF4a leads to increased
cellular proliferation, progression and dedifferentiation
[62,63,64,65,66]. This suggests that HNF4a may act as a tumor
suppressor in epithelial carcinogenesis [61]. Interestingly, although
HNF4a was not affected, we found that numerous downstream
targets of this gene are downregulated specifically in AC. Thus,
this may have the same net affect as inactivation of HNF4a itself
and lead to increased cellular proliferation during AC tumorigen-
esis.
Concerted alterations to gene networks and pathways are not a
feature that is limited to copy-number regulated genes. Indeed, we
found that coupling subtype-specific DNA methylation profiles
with matched gene expression alterations implicated numerous
canonical signaling pathways in the differential development of
SqCC and AC tumors. The enrichment of small-cell lung cancer
signaling pathway members within the epigenetically altered
SqCC genes was of particular interest. For example, one of the
deregulated components of this pathway, the transcription factor
E2F1, was found to exhibit SqCC-specific hypomethylation and
overexpression. E2F1 is upregulated in SCLC tumors [40], which
suppresses apoptosis and induces expression of EZH2,a n
oncogenic polycomb histone-methyltransferase [39]. The rele-
vance of this pathway in SqCC tumors is strengthened by our
observation that EZH2 expression is significantly higher in SqCC
than AC (Figure 5). This is particularly interesting given the
potential dual role of EZH2 in different cancer types [67]. The
disruption of the polycomb group (preferentially in SqCC) is
relevant because we have also identified SqCC-specific deregula-
tion of numerous histone-modifying enzymes by DNA copy
number alterations.
In addition to the deregulation of histone modifying genes by
DNA copy number and DNA methylation alterations, we have
uncovered evidence of global SqCC-specific epigenetic disruption.
Our analysis of global DNA methylation levels in AC and SqCC
tumors showed that SqCC tumors were more hypomethylated
overall, suggesting that the epigenetic machinery is highly
deregulated in SqCC (Figure 4). There is precedent for this
finding, as altered global methylation is thought to be a
consequence of exposure to the carcinogens found in tobacco
smoke [37,38,68]. Global hypomethylation, such as that caused by
cigarette smoke, is also known to be associated with chromosomal
instability. Although we did not observe any difference in the
percentage of AC or SqCC genomes that were altered by copy
number, we did identify a greater number of recurrent copy
number alterations in the SqCC subtype. This may be indicative
of similar selective pressures in the SqCC tumors that facilitate the
development of recurrent alterations, whereas those in AC may be
more diverse, leading to greater heterogeneity.
Concerted DNA copy number and DNA methylation alter-
ations yield insight into tumor biology as well. We show
hypermethylation and deletion of FHIT to be a SqCC-specific
event, confirming earlier studies describing inactivation of the gene
at a higher frequency in SqCC than AC tumors [42,46,69,70].
While there were relatively few genes that were simultaneously
activated/inactivated in SqCC by DNA copy number and
methylation alterations (32), there was no overlap seen in AC. In
fact, compared to SqCC tumors, AC tumors possessed fewer
subtype-specific alterations linked to both DNA copy number and
DNA methylation. The reason for this is not clear, but it is possible
that AC tumors have higher levels of cellular and/or genetic
heterogeneity than SqCC tumors. Heterogeneity of patient
clinical-characteristics may also contribute to this, as lung cancer
in non-smokers are more likely to appear as AC tumors, and
cigarette smoke may play a role in contributing to specific genetic
or epigenetic alterations [71,72]. Nevertheless, although a high
proportion of our AC tumors were from never smokers (22.5%),
no significant differences in copy number were identified between
AC tumors from ever and never smokers (data not shown),
suggesting that this is not a confounding factor in our analysis.
The specific alterations selected during the development of each
subtype may also play a role in the clinical management of disease,
such as influencing treatment outcomes. Indeed, genes already
known to influence NSCLC response to conventional chemother-
apy were deregulated in a subtype-specific manner. For example,
the finding that ERCC1 disruption was subtype-specific is
significant. ERCC1 is a nucleotide excision repair gene which
repairs DNA adducts and lesions induced by smoking-related
carcinogens [73]. As such, low expression levels of ERCC1 have
been implicated in lung cancer susceptibility [74] and tumorigen-
esis, whereas high expression levels are associated with favorable
overall prognosis [73]. However, since ERCC1 is also involved in
the repair of cisplatin-induced DNA adducts in cancer cells, high
expression levels increase resistance to platinum-based chemo-
therapies [75,76], while low expression leads to drug sensitivity
[77]. Underscoring the relevance of this finding are the results of
recent clinical trials that have described a significantly better
outcome for patients who received adjuvant cisplatin-based
combination chemotherapy if their resected tumors expressed
low levels of ERCC1 [73,75]. Our finding that this gene is
inactivated specifically in AC tumors has major clinical conse-
quences in terms of guiding disease management and treatment
strategies in order to define appropriate treatment regimens for
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the subtype specificity of ERCC1 expression levels in NSCLC, and
further highlights how biological differences between AC and
SqCC may influence patient response to therapy [78].
Importantly, numerous genomic regions showed opposite
patterns of alteration in each lung cancer subtype. For example,
a discrete alteration spanning 2.4 Mbp on chromosome bands
8p12-p11.23 was commonly gained in SqCC and lost in AC,
implying that genes in these regions may play opposite roles during
the development of the individual NSCLC subtypes, acting as
TSGs in AC and as oncogenes in SqCC. Such diametric alteration
is seen when including epigenomic alterations as well. This is the
case for PARP11, which is upregulated in SqCC by DNA
hypomethylation and downregulated in AC by copy number loss
(Table S8). This information will become particularly important as
targeted therapeutic strategies based around these genes develop.
The development of MEK inhibitors highlights this point [72]:
since activated MEK1 and MEK2 phosphorylate and activate
ERK (MAPK1), the differential deregulation of MAPK1 in AC
(inactivated) and SqCC (activated) tumors may be an important
consideration in determining the efficacy of this treatment against
lung cancer subtypes [79].
Similarly, numerous studies have aimed to identify genes
associated with prognosis in NSCLC in order to better determine
patient outcome [80]. Our data suggest that these relationships
may be subtype-specific as well (Table S10). Importantly, we
discovered that specific genes may be indicative of totally different
clinical outcomes depending on which subtype they are disrupted
in. For example, CD9 was gain/overexpressed in SqCC and high
expression of this gene correlated with favorable survival in this
subtype as well (Figure 7). However, the opposite was true in AC,
which displayed copy number loss and underexpression; low
expression was associated with good survival and high expression
with poor survival. Together, these results indicate that the genes
involved in defining clinical characteristics are largely exclusive to
individual NSCLC subtypes and influenced by the acquisition of
distinct genetic alterations during tumor development. In addition,
this underlines the importance of separating AC and SqCC when
assessing genes involved in predicting patient prognosis and other
clinical outcomes.
Furthermore, in order to demonstrate how these findings can be
used to define treatment strategies tailored to the individual lung
cancer subtypes, we performed CMAP analysis using our AC and
SqCC specific gene signatures to identify compounds that can
potentially reverse the expression of these genes. Although the
results for AC were uninformative, the SqCC CMAP analysis
identified numerous HDAC and PI3K/mTOR inhibitors as
compounds that could potentially induce a gene expression
signature negatively correlated with that associated with SqCC
(Table S11). The HDAC inhibitor result was remarkable as the
alteration of histone modifying enzymes was the most prominent
network disrupted in this subtype, providing a biological basis for
this finding. Furthermore, cancer cells with elevated activity of
E2F1 have been shown to be highly susceptible to HDAC
inhibitor induced cell death and more recently HDAC inhibitors
such as SAHA have been shown to suppress the activity of EZH2
[81,82]. As E2F1 and EZH2 are both upregulated in SqCC
(Figure 5), this data suggests that treatment with HDAC inhibitors,
in conjunction with standard chemotherapy, could be a promising
avenue for disease treatment. In addition, since PIK3CA activation
(mutation and/or amplification) is known to occur more frequently
in SqCC than AC the finding of multiple PI3K/mTOR inhibitors
as potential therapeutics for SqCC is also logical [51,75].
Together, this data demonstrates the potential to use information
about the underlying molecular biology of the cancer subtypes to
make informed decisions about clinical management strategies and
suggests that HDAC and PIK3/mTOR inhibitors, in combination
with current treatment regimes, may provide a novel treatment
tailored to lung SqCC.
Lastly, it is important to note that although they display broadly
unifying characteristics, AC and SqCC themselves are very
heterogeneous tumor types, with many molecular, pathologic
and clinical subtypes [83,84]. We suggest that our analysis has
revealed the common initiating molecular changes for AC and
SqCC, which may be followed by secondary driver mutations that
cause the subsequent heterogeneity seen in advanced tumors. This
is supported by the fact that we identified SqCC specific
alterations in preinvasive CIS lesions, suggesting that these
alterations commence early in tumor development (Table S3).
By identifying these ‘‘root’’ changes, one may be able to utilize
type specific therapies either in combination with, or followed by,
individualized therapies that target the secondary alterations to
achieve a more complete antitumor response.
Conclusions
Fundamental discrepancies in tumor biology may be a primary
factor determining the differential outcomes of lung cancer
patients. Biological differences that segregate with cell lineages
may also lead to differences in response to therapies [85].
Therefore, tumor cell lineage may be an important consideration
when selecting and developing therapeutic approaches for lung
cancer. An example of this is already in common practice as
SCLC and NSCLC are treated separately due to the observation
that cancers of the former lineage tend to be much more
responsive to initial treatment with conventional cytotoxic agents.
In contrast, no clinical distinction is made between the different
subtypes of NSCLC and stage is the primary factor that determine
treatment options. Our high-resolution integrative analysis of
NSCLC genomes and epigenomes delineated novel tumor
subtype-specific genetic and epigenetic alterations responsible for
driving the differential pathogenesis and phenotypes of AC and
SqCC. The specific genes and networks identified in this study
provide essential starting insights for elucidating mechanisms of
tumor differentiation and developing tailored therapeutics for lung
cancer treatment. More generally, our results confirm at the
molecular level that these lung cancer subtypes are distinct disease
entities. When designing new treatment strategies and testing new
drugs in clinical trials, these subtype differences as well as the
biological pathways should be taken into account.
Materials and Methods
Ethics Statement
All patient samples were collected under informed, written
patient consent and anonymized as approved by the University of
British Columbia–British Columbia Cancer Agency Research
Ethics Board (REB number H04-60060).
DNA samples
Formalin-fixed, paraffin embedded (FFPE) and fresh-frozen
tissues were collected from St. Paul’s Hospital, Vancouver General
Hospital and Princess Margaret Hospital following approval by
the Research Ethics Boards. Hematoxylin and eosin stained
sections for each sample were graded by a lung pathologist for use
in selecting regions for microdissection. DNA was isolated using
standard procedure with proteinase K digestion followed by
phenol-chloroform extraction as previously described [86]. Patient
information is located in Table 1.
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Array hybridization was performed as previously described
[30,87,88]. Briefly, equal amounts (200–400 ng) of sample (extract-
ed from either fresh-frozen or FFPE tissues) and single male
reference genomic DNA were differentially labelled and hybridized
to SMRT array v.2 (BCCRC Array Laboratory, Vancouver, BC),
which is previously described to give optimal genome coverage
[27,89].
Hybridized arrays were imaged using a charge-coupled device
(CCD) camera system and analyzed using SoftWoRx Tracker Spot
Analysis software (Applied Precision, Issaquah, WA). Systematic
biases were removed from all array data files using a stepwise
normalization procedure as previously described [29,32]. SeeGH
softwarewasusedtocombinereplicatesandvisualizealldataaslog2
ratio plots [90,91]. Stringently, all replicate spots with a standard
deviation above 0.075 or signal to noise ratios below three were
removed from further analysis. The probes were then positioned
based on the human March 2006 (hg 18) genome assembly.
Genomic imbalances (gains and losses) within each sample were
identified using aCGH-Smooth [28] with lambda and breakpoint per
chromosome settings at 6.75 and 100, respectively (as previously
described) [30]. The resulting frequency of alteration was then
determined for each lung cancer cell type as described previously
[30].
DNA Methylation Analysis
For 30 AC samples, 30 patient-matched non-malignant lung
samples, 13 SqCC samples and 18 non-patient matched bronchial
epithelia samples (all fresh-frozen samples), DNA methylation
profiling was performed using the Illumina HumanMethylation27
chip. Five hundred nanograms of DNA from each sample were
analyzed by this technology. Normalized b-values were obtained
and only those with a detection p-value of #0.05 were used. When
comparing tumor samples (AC/SqCC) and normal non-malignant
samples (AC non-malignant parenchyma and bronchial epithelia),
probesweredeemedaberrantlymethylatediftheabsolutedifference
between tumor and the average of the appropriate normal samples
was $0.15.
Comparison of subtype alteration frequencies
Regions of differential copy number alteration between AC and
SqCC genomes were identified as follows. Each array element was
scored as 1 (gain/amplification), 0 (neutral/retention), or 21 (loss/
deleted) for each individual sample. Values for elements filtered
based on quality control criteria were inferred by using neighbour-
ingprobeswithin10 Mb.Probeswerethenaggregatedintogenomic
regions if the similarity in copy number status between adjacent
probes was at least 90% across all samples from the same subtype.
The occurrence of copy number gain/amplification, loss/deletion,
and retention at each locus was then compared between AC and
SqCC data sets using the Fisher’s exact test. Testing was performed
usingtheRstatisticalcomputingenvironmentona362contingency
table as previously described, generating a p-value for each probe
[30]. A Benjamini-Hochberg multiple hypothesis testing correction
based onthe numberofdistinctregionswasappliedand resultingp-
values #0.01 were considered significant. Adjacent regions within
1 Mb which matched both the direction of copy number difference
andstatisticalsignificancewerethenmerged.Finally,regionshadto
bealteredin.20%ofsamplesinagroupandthedifferencebetween
groups .10% to be considered.
A similar approach was used for determining subtype-specific
DNAmethylationalterations.Frequenciesofhypermethylationand
hypomethylation for each probe were compared using a Fisher’s
exact test, followed by a Benjamini-Hochberg multiple testing
correction.Acorrectedp-valuecut-offofp,0.05wasusedtodeema
probe differentially methylated between the two groups.
Gene expression microarray analysis
Fresh-frozen lung tumors were obtained from Vancouver
General Hospital as described above. Microdissection of tumor
cells was performed and total RNA was isolated using RNeasy Mini
Kits (Qiagen Inc., Mississauga, ON). Samples were labeled and
hybridized to a custom Affymetrix microarray according to the
manufacture’s protocols (Affymetrix Inc., Santa Clara, CA). In
addition, RNA was obtained from exfoliated bronchial cells of lung
cancer free individuals obtained during fluorescence bronchoscopy
[71]. All individuals were either current or former smokers.
Expressionprofilesweregenerated forallcasesusingtheAffymetrix
U133 Plus 2 platform (Affymetrix Inc., Santa Clara, CA). All data
was normalized using the Robust Multichip Average (RMA)
algorithm in [92]. In addition, publically available datasets
downloaded from the Gene Expression Omnibus were used: Affymetrix
U133Plus2expressiondatawasdownloadedforaccessionnumbers
GSE3141 [93] and GSE8894 [48].
Statistical analysis of gene expression data
Gene expression probes were mapped to March 2006 (hg 18)
genomic coordinates and those within the regions of copy number
difference between the subtypes were determined. Comparisons
betweenexpressionlevelsforACandSqCCtumorswereperformed
using the Mann-Whitney U test and computed with the ranksum
functioninMatlab.Asthedirectionofgeneexpressiondifferencewas
predicted to match the direction of copy number difference, one
tailed p-values were calculated. A Benjamini-Hochberg multiple
hypothesis testing correction wasapplied based on the total number
of gene expression probes analyzed for each region. Probes with a
corrected p-value#0.001 were considered significant. If multiple
probesmappedtothesamegene,theonewiththelowestp-valuewas
used. Resulting genes were then mapped to the corresponding
probes on the Affymetrix U133 Plus 2 array in order to compare
theirexpressioninasecondsetofNSCLCtumors(GSE3141above)
against normal bronchial epithelial cells. If multiple probes were
present for a gene, the one with the strongest p-value was used. All
comparisons were performed using a one-tailed t-test with unequal
variances in Excel and genes with a p,0.001 were considered
significant. The fold-change for tumors versus normal tissues was
Table 1. Sample set clinical characteristics.
AC (n=169) SqCC (n=92)
Stage* I 76 (44.9%) 32 (34.7%)
II 40 (23.6%) 32 (34.7%)
III 22 (13%) 14 (15.2%)
IV 27 (16.0%) 10 (10.9%)
n/a 4 (2.4%) 4 (4.4%)
Sex Female 106 (62.7%) 26 (28.3%)
Male 63 (37.3%) 66 (71.7%)
Smoking Status Current smoker 48 (28.4%) 30 (32.6%)
Ex-smoker 80 (47.3%) 61 (66.3%)
n/a 3 (1.8%)
Non-smoker 38 (22.5%) 1 (1.1%)
*6th Edition UICC/AJCC classification criteria.
doi:10.1371/journal.pone.0037775.t001
The Molecular Basis of Lung Cancer Subtypes
PLoS ONE | www.plosone.org 15 May 2012 | Volume 7 | Issue 5 | e37775then determined in order to determine genes expressed in the
direction predicted by copy number.
Principle component analysis was performed using expression
data for the three independent tumor data sets (described above) in
MATLAB. All genes of interest with probes on the corresponding
arrays were used. Briefly, the first and second principal components
were generated from the original dataset. In the subsequent
validation in secondary datasets, these principal components are
then used to weight the expression data for a gene based on the
originaldistribution.TheReceiverOperatingCharacteristic(ROC)
areaunderthecurve(AUC)analysiswasperformedtodeterminethe
ability of principle component 1 to separate the AC and SqCC
samples into their appropriate histological groups. Calculations
were performed using the GraphPad Prism software.
Connectivity Map (http://www.broad.mit.edu/cmap/) analysis
was performed using the up and downregulated genes specific to
each subtype as previously described [50].
Survival analysis
Survival analysis was performed using the statistical toolbox in
Matlab. Expression data for each gene were sorted and survival
times were compared between the top 1/3 and bottom 1/3 in
expression using a publicly available gene expression microarray
dataset with survival data (Table S1). Two tailed p-values were
generated using a Mantel-Cox log test and those ,0.05 were
considered significant. Kaplan-Meier plots were then generated
for each gene of interest.
Network identification
Functional identification of gene networks and canonical
signalling pathways was performed using Ingenuity Pathway
Analysis program (IngenuityH Systems, www.ingenuity.com). AC
and SqCC specific gene lists were imported as individual
experiments using the Core Analysis tool. The analysis was
performed using Ingenuity Knowledge Database with the
Affymetrix U133 Plus 2 platform as the reference set and was
limited to direct and indirect relationships.
Human lung tissue tissue microarray case selection
To determine the expression of ERCC1, KEAP1 and SOX2 in
primary NSCLC, we selected 330 NSCLCs (AC, n=220; SqCC,
n=110) from surgically resected lung cancer specimens from the
Lung Cancer Specialized Program of Research Excellence Tissue-
Bank at The University of Texas M.D. Anderson Cancer Center.
Weusedarchived,formalin-fixed,paraffin-embedded(FFPE)tumor
tissuesamplesplacedintissuemicro-array(TMA).Thetumortissue
samples were collected between 1997 and 2003, and were
histologically analyzed and classified using the 2004 WHO
classification system [94]. The characteristics of these TMAs have
been previously described in detail [95,96].
Immunohistochemical analysis
Theimmunohistochemicalanalysiswasdoneusingcommercially
available antibodies against KEAP1 (dilution1:25; Proteintech,
Chicago, IL), ERCC1 (dilution 1:25; Labvision, Fremont, CA) and
SOX2 (dilution 1:50; R&D system, Minneapolis, MN). Immuno-
histochemical staining was done using an automated stainer (Dako,
Inc.) with 5-mm-thick TMA sections from FFPE tissues. Tissue
sections were deparaffinized and hydrated. Antigen retrieval was
doneinpH 6.0citratebufferinadecloakingchamber(121uC630 -
seconds, 90uC610 seconds) and washed on Tris buffer. Peroxide
blocking was done at ambient temperature with 3% H2O2 in
methanol. The slides were incubated with primary antibody
(KEAP1 and ERCC1 for 60 minutes; SOX2 for 90 minutes) at
ambient temperature and washed with Tris buffer, followed by
incubation with biotin-labeled secondary antibody for 30 minutes
(EnVision Dual Link System-HRP-Dako for KEAP1 and ERCC1;
LSABsystem-DakoforSOX2).Theimmunostainingwasdeveloped
with0.5%3,39-diaminobenzidine,freshlypreparedwithimidazole-
HCl buffer (pH 7.5) containing hydrogen peroxide and an
antimicrobial agent (Dako) for 5 minutes, and then the slides were
counterstained with hematoxylin, dehydrated, and mounted.
Nuclear ERCC1, cytoplasmic KEAP1, and nuclear SOX2
expressions were quantified using a four-value intensity score (0,
1+,2 +,o r3 +) and the percentage (0–100%) of the extent of
reactivity. An immunohistochemical expression score was obtained
by multiplying the intensity and reactivity extension values (range,
0–300), and these expression scores were used to determine
expression levels.
Trichostatin A dose-response analysis
The effect of HDAC inhibitor Trichostatin A, (Cayman
Chemicals, Denver, CO, USA) on six NSCLC cell lines; three
adenocarcinoma (H3255, H1395 and A549) and three SqCC lines
(HCC95, HCC15 and H520) was assessed by cell viability assays.
Cellswereplatedintriplicatein96wellplatesatoptimaldensitiesfor
growth (A549 at 2000 cells/well, HCC95, HCC15 and H520 at
3000 cells/well, and H3255 and H1395 at 6000 cells/well). Cells
were subjected to a series of 2-fold dilutions of Trichostatin A
prepared in cell growth media and DMSO. The experimental
inhibitor concentrations ranged from 100 uM to 109 pM and the
final DMSO concentration for treated and untreated (control) cells
was 1%. Blank wells contained equal volumes of growth media with
1% DMSO. Cells were incubated for 72 hours at 37uC and then
treated with 10 ml of Alamar Blue cell viability reagent (Invitrogen,
Carlsbad, CA, USA) according to manufacturer’s instructions. The
reaction product was quantified by measuring absorbance at
570 nm with reference to 600 nm using an EMax plate reader
(Molecular Devices, Sunnyvale, CA, USA). The response of treated
cells was measured as a proportion of the viability of untreated cells,
with the mean background subtracted treatment absorbance
divided by the mean background subtracted untreated absorbance
for each inhibitor concentration. Dose response curves and IC50
values were generated in Graph Pad v5 using the proportionate
response of all 20 drug concentrations. Experiments were repeated
in quadruplicate and differences in IC50 values were determined
using a student’s t-test with a p-value,0.05 considered significant.
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